A GROUP OF PEPTIDE DERIVATIVE OMICSYNINS WITH ANTIVIRAL ACTIVITY AND USES THEREOF

Abstract

This disclosure related to a group of peptide derivative Omicsynins with antiviral activity against influenza virus and coronavirus. It also related uses of these derivatives, the chemical formula of the peptide derivative Omicsynins is shown in formula (1):

##STR00001##

TABLE-US-00001 R1—R4 are shown in the following table. NO. substituent1 substituent2 substituent3 R.sub.1 [00002] [00003] [00004]Basic amino-acid side chains including lysine, histidine, citrulline residues, and etc. R.sub.2 [00005] —CH(CH.sub.3).sub.2, —CH(CH.sub.3)CH.sub.2CH.sub.3 —CH.sub.2CH(CH.sub.3).sub.2 Neutral amino-acid side chain including tryptophan, serine, threonine, cysteine residues and etc. R.sub.3 [00006] [00007] [00008][00009]R.sub.3 including tyrosine, lysine, histidine, citrulline residues, and etc. R.sub.4 —CH.sub.2OH —CHO R.sub.4 including —CH.sub.2NH.sub.2, —CH═NH,— CH═NOH, —COOH, —COOR.sub.5 (R.sub.5 represents alkyl groups containing 1-3 carbons), -CONH.sub.2 and etc.

Claims

1. Uses of a group of peptide derivative Omicsynins for the treatment of a virus infection, wherein the chemical formula of the peptides derivative Omicsynins is shown in formula (1), ##STR00064## wherein R .sub.1-R.sub.4 are shown in the following table, TABLE-US-00015 NO. substituent 1 substituent 2 substituent 3 R.sub.1 Basic amino-acid side chains including lysine, histidine, citrulline residues, and etc. R.sub.2 CH(CH.sub.3).sub.2 CH(CH.sub.3)CH.sub.2CH.sub.3 -CH.sub.2CH(CH.sub.3).sub.2 Neutral amino-acid side chain including tryptophan, serine, threonine, cysteine residues and etc. R.sub.3 R.sub.3 including tyrosine, lysine, histidine, citrulline residues, and etc. R.sub.4 CH.sub.2OH CHO R.sub.4 including —CH.sub.2NH.sub.2¸CH═NH¸CH═NOH¸COOH¸ COORs (R.sub.5 represents alkyl groups containing 1-3 carbons) ¸CONH.sub.2 and etc. wherein the virus is influenza virus or coronavirus.

2. (canceled)

3. (canceled)

4. A group of peptide derivative Omicsynins, Omicsynin, B1, B2, B3, B5, B6, the general structural formula is shown in formula (1), ##STR00073## wherein the substituents of R .sub.1~R.sub.4 of each compound are shown in the following table: TABLE-US-00016 Name R.sub.1 R.sub.2 Omicsynin B1 Omicsynin B2 Omicsynin B3 CH (CH.sub.3) .sub.2 Omicsynin B5 CH(CH.sub.3)CH.sub.2CH.sub.3 Or —CH.sub.2CH(CH.sub.3).sub.2 Omicsynin B6 CH(CH.sub.3)CH.sub.2CH.sub.3 Or —CH.sub.2CH(CH.sub.3).sub.2 Omicsynin B1 CHO Omicsynin B2 CHO Omicsynin B3 CHO Omicsynin B5 CHO Omicsynin B6 CHO .

5. A biosynthetic gene clusters for the production of peptide derivative Omicsynins in a microorganism, wherein the gene cluster is of Streptomyces sp. CPCC 200451 genome Chromosome 1: 7,822,964-7,875,615, with a full length of 52.6 kb, and wherein the chemical formula of the peptides derivative Omicsynins is shown in formula (1): ##STR00086## wherein R.sub.1-R.sub.4 are shown in the following table: TABLE-US-00017 NO. substituent 1 substituent 2 substituent 3 R.sub.1 Basic amino-acid side chains including lysine, histidine, citrulline residues, and etc. R.sub.2 CH(CH.sub.3).sub.2¸ CH(CH.sub.3)CH.sub.2CH.sub.3 —CH.sub.2CH(CH.sub.3).sub.2 Neutral amino-acid side chain including tryptophan, serine, threonine, cysteine residues and etc. R.sub.3 R.sub.3 including tyrosine, lysine, histidine, citrulline residues¸ and etc. R.sub.4 CH.sub.2OH CHO R.sub.4 including —CH.sub.2NH.sub.2¸CH═NH¸CH═NOH, —COOH¸ COORs (R.sub.5 represents alkyl groups containing 1-3 carbons) ¸CONH.sub.2 and etc.

6. The biosynthetic gene cluster according to claim 5, wherein gene 7094 and 7098 in said gene cluster are key biosynthetic genes of peptide derivative Omicsynins, and the amino acid sequences of the encoded proteins are shown in SEQ ID NO:1 and 2, and gene 7102 in said gene cluster is a positive regulator of the peptide derivative Omicsynins synthetic gene, the amino acid sequence of the encoded protein is shown in SEQ ID NO:3, and its expression level is in proportion to the content of Omicsynins.

7. (canceled)

8. Use of the gene cluster of claim 9 to ptrpare peptides derivative Omicsynins showed in formula (1) by microbial fermentation: ##STR00095## wherein R.sub.1-R.sub.4 are shown in the following table: TABLE-US-00018 NO. substituent 1 substituent 2 substituent 3 R.sub.1 Basic amino-acid side chains including lysine, histidine, citrulline residues, and etc. R.sub.2 —CH(CH.sub.3).sub.2, —CH(CH.sub.3)CH.sub.2CH.sub.3 —CH.sub.2CH(CH.sub.3).sub.2 Neutral amino-acid side chain including tryptophan, serine, threonine, cysteine residues and etc. R.sub.3 R.sub.3 including tyrosine, lysine, histidine, citrulline residues and etc. R.sub.4 CH.sub.2OH CHO R.sub.4 including —CH.sub.2NH.sub.2¸CH═NH¸CH═NOH¸ —COOH¸ —COOR.sub.5 (R.sub.5 represents alkyl groups containing 1-3 carbons) ¸CONH.sub.2 and etc.

9. The biosynthetic gene cluster according to claim 5, wherein the gene cluster is between gene 7092-7102 (chromosome 1: 7,841,516-7,857,514), with a full length of 15.99 kb.

Description

DESCRIPTION OF THE FIGURES

[0044] FIG. 1. Genome-wide transcriptome alignment of Streptomyces sp. CPCC 200451 under different active fermentation conditions.

[0045] FIG. 2. Transcriptome alignment at cluster 27 of Streptomyces sp. CPCC 200451 under different active fermentation conditions.

[0046] FIG. 3. Transcriptome alignment at cluster 28 of Streptomyces sp. CPCC 200451 under different active fermentation conditions.

[0047] FIG. 4. Transcriptome alignment at cluster 36 of Streptomyces sp. CPCC 200451 under different active fermentation conditions.

[0048] FIG. 5. Gene expression levels of clusters 27 in Streptomyces CPCC 200451 as detected by qRT-PCR.

[0049] FIG. 6. Gene expression levels of clusters 28 in Streptomyces CPCC 200451 as detected by qRT-PCR.

[0050] FIG. 7. Gene expression levels of clusters 36 in Streptomyces CPCC 200451 as detected by qRT-PCR.

[0051] FIG. 8. Transcriptome alignment at Cluster 36 of Streptomyces CPCC 200451 in A1, A3 and A3-Fe3+ media.

[0052] FIG. 9. Gene expression levels of clusters 36 of Streptomyces CPCC 200451 in A1, A3 and A3-Fe3+ media as detected by qRT-PCR.

[0053] FIG. 10. Comparation of the Omicsynin gene cluster and the deimino-antipain gene cluster, and their amino acid sequence identities.

[0054] FIG. 11. Biosynthetic gene clusters of Deimino-antipain and related natural products

[0055] FIG. 12. Electropherogram of plasmid pOJ7094LR by enzyme digestion

[0056] FIG. 13. Electropherogram of plasmid pOJ7098LR by enzyme digestion

[0057] FIG. 14. PCR screening of single/double crossover mutants of Streptomyces CPCC 200451

[0058] FIG. 15. PCR screening of gene 7094 double-crossover mutants of Streptomyces CPCC 200451

[0059] FIG. 16. PCR screening of gene 7098 double-crossover mutants of Streptomyces CPCC 200451

[0060] FIG. 17. The qRT-PCR analysis of gene expression levels in the core NRPS region of cluster 36 in the WT strain, 7094 gene knockout mutant (7094-KO)

[0061] FIG. 18. The qRT-PCR analysis of gene expression levels in the core NRPS region of cluster 36 in the WT strain, 7098 gene knockout mutant (7098-KO)

[0062] FIG. 19. Transcriptome alignment results of cluster 36 between the WT strain (black) and gene 7102 overexpression strain (blue, 1647/pL-7102) cultured in A1 medium

[0063] FIG. 20. The qRT-PCR analysis of gene expression levels in the core NRPS region of cluster 36 between the WT strain (black) and gene 7102 overexpression strain (blue, 1647/pL-7102) cultured in A1 medium

[0064] FIG. 21. Separation process and technical route of active compounds

[0065] FIG. 22. Chemical structures of Omicsynins A1 and A2

[0066] FIG. 23. NMR spectra for Omicsynin A1. (a) 1H-NMR in DMSO-d6, (b) 13C-NMR in DMSO-d6, (c) DEPT in DMSO-d6, (d) 1H-1H COSY in DMSO-d6, (e) HSQC in DMSO-d6, (f) HMBC in DMSO-d6, (g) 1H-1H NOESY in DMSO-d6, (h) HRMS Spectrum

[0067] FIG. 24. NMR spectra for Omicsynin A2. (a) 1H-NMR in DMSO-d6, (b) 13C-NMR in DMSO-d6, (c) DEPT in DMSO-d6, (d) 1H-1H COSY in DMSO-d6, (e) HSQC in DMSO-d6, (f) HMBC in DMSO-d6, (g) 1H-1H NOESY in DMSO-d6, (h) HRMS Spectrum

[0068] FIG. 25. Determination of the absolute configuration of Omicsynin A1 (25A-F) and Omicsynin A2 (25G-H)

[0069] FIG. 26. HRMS Spectrum of Omichin A6

[0070] FIG. 27. HRMS Spectrum of Omichin B1

[0071] FIG. 28. HRMS Spectrum of Omichin B2

[0072] FIG. 29. HRMS Spectrum of Omichin B3

[0073] FIG. 30. HRMS Spectrum of Omichin B5

[0074] FIG. 31. HRMS Spectrum of Omichin B6

[0075] FIG. 32. HRMS Spectrum of Omichin C1

[0076] FIG. 33. HRMS Spectrum of Omichin C2

[0077] FIG. 34. HRMS Spectrum of Omichin C6

[0078] FIG. 35. The effect of Omicyxin B4 on the mRNA expression level of the N protein of HCoV-OC43 in C3A cells by qRT-PCR assays.

DETAILED DESCRIPTION OF THE EMBODIMENTS

Materials and Methods

[0079] Strain: [0080] Streptomyces sp. CPCC 200451 (China Pharmaceutical Culture Collection No. CPCC 200451), [0081] Escherichia coli (E. coli) DH5a [0082] E. coli ET12567/pUZ8002,

[0083] Plasmid: [0084] pSET152, pSET152 derivative plasmid containing the constitutive promoter ermE*p, Amr, [0085] pOJ260, E. coli vector, nonreplicating in Streptomyces, Amr,

TABLE-US-00004 Primers: Primer Oligonucleotide (5′ to 3′) Restrictio n site Purpose 7081-F TACATATGGTTGCGGTGGTGCGGCAGGA NdeI Used for amplifying gene 7081 7081-R GATCTAGACTGTTTGTTTCTGGGCGGA XbaI 7082-F GTACATATGGTCGTCGTGGAAATCCGGGT NdeI Used for amplifying gene 7082 7082-R TAGGATCCCAACAATCTCCGACGCATCC BamHI 7083-F TACATATGCCCACCGACGTGTTCGGCGC NdeI Used for amplifying gene 7083 7083-R TAGGATCCGAACTTCTCGCAGGTGATCG BamHI 7089-F TACATATGGAACTGCGGCAGCTCCAGTA NdeI Used for amplifying gene 7089 7089-R GATCTAGAAGTTGACGGAGGCCAAGC XbaI 7102-F TATCTAGAACCGACGGCAGCTCAGAGCG NdeI Used for amplifying gene 7102 7102-R TAGGATCCGCGGTGTCACCTCGTGTCCC BamHI 7098-F TACATATGACCACCGCGACCCTGCCCGC NdeI Used for amplifying gene 7098 7098-R TAGGATCCTCATCGGGCCGCTCCCCGGG BamHI 7098 Left arm-F CCTAAGCTTGAGTTCCTGTACCGCTACGT HindIII Used for amplifying the left arm of gene 7098 7098 Left arm-F TAGAATTCGGTGGTCCCTTCCGGGCGCC EcoRI 7098 Right arm-F TAGAATTCGCGCCGTGGACCAGGCCGAA EcoRI Used for amplifying the right arm of gene 7098 7098 Right arm-R attB- Streptomyces CCTAAGCTTGTGCAGGCGGAGTGGATCCGGTGGGGGTGCCAGGG HindIII - Used for verifying the integration of ΦC31 attB site pSET152 TTCGGCGGCTTCAAGTTCGG - 7098_KOcheckP 1 CGAGTACCAGCACGTCCA - Used for verifying 7098_KOcheckP 2 GCTCGGTCTTGGTGTCGA - the gene 7098 knockout strain 7098_KOcheckP 3 CCCACCGACAACTTCCTGG - 7098_KOcheckP 4 GATCCGCTCGCAGTCCAG - 7098_KOcheckP 5 CTCCACCGTCCTCACCTAC - 7098_KOcheckP 6 CGATCCAGAGTTCGCCGA - hrdB-RT1 CTCATCGAGCGGGGCAAG - Used for the detection of hrdB transcription hrdB-RT2 CCCTCCTCAATCAGCACCTG - 5814RT1 GAAACTGATCCCGCGCAC - Used for the detection of gene 5814 transcription 5814RT2 CAGCACGCACAGGTACAC - 5819RT1 CTCGCCGAGGACCACATC - Used for the detection of gene 5819 transcription 5819RT2 GACCATCCAGAGCACCGG - 5821RT1 CTGCTGTTCCGGGCCTTC - Used for the detection of gene 5821 transcription 5821RT2 CAGGAGAGGTGTTCGGTGAG - 7090RT1 GGCCTCGACATCACCGTG - Used for the detection of gene 7090 transcription 7090RT2 CGAAGAAACGCAGGGAGAAG - 7091RT1 GGAAGCCAGGTCACCGAT - Used for the detection of gene 7091 transcription Used for the detection of gene 7092 transcription Used for the 7091RT2 CATCGGATCGCCCCAGTAG - 7092RT1 GGCTGATCTGGCTGTCGA - 7092RT2 CATGGTGGCGTTCATCCG - 7093RT1 CGCTACGCCTGCTGATCG - 7093RT2 GAGTACCCCGAGCGACTG - detection of gene 7093 transcription 7094RT1 ACCTGTTCACCGTCTACCG - Used for the detection of gene 7094 transcription 7094RT2 AGCTCCTTGGTCCAGAAGTC - 7096RT1 CTGGGTGATCAACGGGCG - Used for the detection of gene 7096 transcription 7096RT2 CTGGTCCATCGGCAGCAC - 7097RT1 GCACGTGATGGAGCTGTG - Used for the detection of gene 7097 transcription 7097RT2 AGGATGGTCGCGGTGATG - 7098RT1 GCCAGTCCCGGATCTTCG - Used for the detection of gene 7098 transcription 7098RT2 GTTGACCAGTTCGAGCCAG - 7099RT1 TCGACACCAAGACCGAGC - Used for the detection of gene 7099 transcription 7099RT2 ATGTGGTGGATCGTCAGGG - 7101RT1 GACGACTGGGACGCCATG - Used for the detection of gene 7101 transcription 7101RT2 GGGGACTTCACGACGTAGG - 7102RT1 GCGGCTCTTCCTCGACTAC - Used for the detection of gene 7102 transcription 7102RT2 CGTCCATCAGTTCGGTGAGG - N sense CGATGAGGCTATTCCGACTAGGT - Used for the detection of gene of N protein of HCoV-OC43 N antisense CCTTCCTGAGCCTTCAATATAGTAACC - Probe-1 TAMRA-TCCGCCTGGCACGGTACTCCCT- BHQ2 - Sense CGGAGTCAACGGATTTGGTCGTAT - Used for the Antisense AGCCTTCTCCATGGTGGTGAAGAC - detection of gene GAPDH Probe-2 TAMRA- CCGTCAAGGCTGAGAACGG - BHQ2 - M2 sense GACCRATCCTGTCACCTCTGAC - Used for the detection of gene of M2 protein of IAV M2 antisense GGGCATTYTGGACAAAKCGTCTACG - β-actin sense AGTCAAGGCTGAGAACGGGAAACT - Used for the detection of gene β-actin β-actin antisense TCCACAACATACTCAGCACCAGCA -

Fermentation Medium

[0086] A1 medium: glucose 0.5%, malt extract 1.0%, cottonseed powder 1.0%, soluble starch 2.0%, yeast extract 0.5%, K2HPO4 0.05%, (NH4)2SO4 0.5%, CaCO3 0.3%, NaCl 0.1%. pH 7.2-7.4.

[0087] A2 medium: glucose 0.5%, yeast extract 0.5%, peptone 0.5%, beef extract 0.5%, corn syrup 0.4%, soybean powder 1.0%, CaCO3 0.4%, CoCl2 0.002%, soluble starch 2.0% glucose 0.5%, yeast extract 0.5%, peptone 0.5%, beef extract 0.5%, corn syrup 0.4%, soybean powder 1.0%, CaCO3 0.4%, CoCl2 0.002%, soluble starch 2.0%, pH 7.2-7.4.

[0088] A3 medium: glycerol 2.0%, dextrin 2.0%, peptone 1.0%, yeast extract 0.5%, (NH4)2SO4 0.2%, CaCO3 0.2%. pH 7.2-7.4.

[0089] A4 medium: soluble starch 3.0%, soybean meal 1.5%, sodium thiosulfate 20 .Math., ferrous sulfate 0.05%, dipotassium hydrogen phosphate 0.05%, potassium chloride 0.03%, pH 7.2-7.4.

[0090] B1 Glucose Asparagine Medium: Glucose 10, Aspartin 0.05%, Dipotassium Hydrogen Phosphate 0.05%, pH 7.2-7.4.

[0091] B2 Synthetic No. 5 medium: potassium nitrate 0.1%, sodium chloride 0.05%, dipotassium hydrogen phosphate 0.05%, ferrous sulfate 0.001%, magnesium sulfate 0.05%, soluble starch 2%, pH 7.0.

[0092] B3 Sodium propionate medium: sodium propionate 0.2%, ammonium nitrate 0.01%, potassium chloride 0.01%, magnesium sulfate 0.005%, ferrous sulfate 0.005%, pH 7.2.

[0093] B4 medium: sodium succinate 0.09%, ammonium dihydrogen phosphate 0.05%, magnesium sulfate 0.01%, ferrous sulfate 0.001%, pH 7.2.

[0094] B5 Waksman medium: ammonium sulfate 0.02%, dipotassium hydrogen phosphate 0.3%, magnesium sulfate 0.05%, calcium chloride 0.0126%, pH 7.2.

[0095] B6 TWYE medium: yeast powder 0.025%, dipotassium hydrogen phosphate 0.05%, pH 7.2.

[0096] B7 Kjeldahl’s synthesis medium 1: K2HPO4 0.1%, CaCO3 0.03%, NaCl 0.02%, KNO3 0.1%, FeSO4.Math.7H2O 0.001%, CaCO3 0.05%, glucose 2.0%, pH 7.0.

[0097] B8 Chaplain medium: sucrose 3%, potassium nitrate 0.2%, dipotassium hydrogen phosphate 0.1%, potassium chloride 0.05%, magnesium sulfate 0.05%, ferrous sulfate 0.001%, pH 7.2-7.4.

[0098] B9 ISP7 medium: tyrosine 0.05%, glycerol 1.5%, asparagine 0.1%, dipotassium hydrogen phosphate 0.05%, magnesium sulfate 0.05%, sodium chloride 0.05%, ferrous sulfate 0.001%, pH 7.2-7.4.

[0099] B10 medium: soluble starch 0.2%, ferrous sulfate 0.001%, magnesium sulfate 0.05%, potassium nitrate 0.1%, sodium chloride 0.04%, dipotassium hydrogen phosphate 0.05%, pH 7.2.

[0100] Other media are conventional standardized media.

[0101] The PH of fermentation media were adjusted using 6 mol.Math.L.sup.-1 NaOH or 6 mol.Math.L.sup.-1 HCl.

Example 1. Cultivation and Sequencing of Streptomyces CPCC 200451

1. Culture and Strain Preservation of Streptomyces Spp. CPCC 200451

[0102] The mycelium of CPCC 200451 was cultured in YMG or TSB liquid medium, and cultured in a shaker at 28° C. and 200 rpm for 36-72 h, when Streptomyces CPCC 200451 was cultured in solid, YMG solid medium was used at 28° C. in an incubator. Cultured for 5-7 days, MS medium was used as the solid medium for sporulation.

[0103] All strains used in the experiment were frozen in glycerol at -20° C. or -80° C.

2. Fermentation of Streptomyces Spp. CPCC 200451

[0104] Streptomyces sp. CPCC 200451 and its derivatives were grown at 28° C. on solid yeast malt glucose (YMG) medium for 7 days, Transfer the mycelium to a 500 mL shake flask containing 100 mL of YMG liquid medium, incubate it at 28° C. and 200 rpm for 48 h on a shaker for seed culture. Then transfer 10% seed to 500 mL shake flasks containing 100 mL of fermentation media, the fermentation broth was collected after culturing at 28° C. and 200 rpm shaker for 5 days.

[0105] TSB medium: peptone 0.2%, sodium chloride 0.5%, glucose 0.25%, dipotassium hydrogen phosphate 0.25%.

[0106] YMG medium: glucose 1%, malt extract 1%, yeast extract 1%, agar 1.5%, pH 7.0.

[0107] MS medium: mannitol 2%, soybean powder 2%, agar 2%, prepared with tap water, magnesium chloride was added at a final concentration of 10 mM at the time of use.

3. Genome Sequencing and Bioinformatic Analysis of Streptomyces Spp. CPCC 200451

[0108] To demystify the structure of antiviral compounds and reveal the biosynthesis mechanism, extraction of the total genomic DNA from Streptomyces sp. CPCC 200451 was carried out, and high-throughput sequencing was performed by the Beijing Genomics Institute (BGI), Shenzhen, China, with the third-generation sequencing Pacbio RSII platform and the second-generation sequencing Illumina Hiseq 4000 platform. Sequence assembly and correction were completed by SMRT Analysis v2.3.0, coupled with SOAPsnp, SOAPindel, and GATK. Glimmer 3.0 software was employed to predict protein-coding sequences (CDSs). Gene functional annotation was performed by blastp searches of the COG, KEGG, TrEMBL, Swiss-Port, NR, and GO databases. The online resource antibiotics and Secondary Metabolite Analysis Shell (antiSMASH) Version 5.0.0† was used to predict secondary metabolic biosynthesis gene clusters.

[0109] The genome of Streptomyces sp. CPCC 200451 is a linear chromosome of approximately 8,918,347 bps, with a GC content of 73.6%. The genome contains a total of 316 tandem repeat sequences with a total length of 151,923 bp, accounting for 1.7% of the total genome length. After gene annotation analysis, it was found that the genome contains 8,151 protein-coding genes, 11 rRNA operons were predicted by rRNAmmer software by aligning the rRNA library, 73 tRNA coding genes were found by tRNAscan-SE software.

Example 2. Analysis and Confirmation of the BGC for the Biosynthesis of Antiviral Active Compounds in Streptomyces sp. CPCC 200451

Activity-Directed Comparative Transcriptomics Analysis

[0110] The regulation of transcription level is one of the most important regulation ways in prokaryotes. In this example, comparative transcriptome analysis of fermentation broth samples with different antiviral activities (high activity, low activity, and no activity) was conducted to preliminarily locate the BGC responsible for the biosynthesis of the antiviral active compounds in Streptomyces sp. 1647.

1. Screening of Fermentation Conditions

[0111] We screened the fermentation conditions of CPCC 200451, tried 14 types of fermentation media and 4 fermentation time points, and determined the antivirus activity of the fermentation broth in order to obtain fermentation broth samples with different antivirus activities,

Screening of Fermentation Medium

[0112] The spore suspension of Streptomyces CPCC 200451 was coated on the surface of YMG solid medium, and after culturing in a 28° C. incubator for 7 days, the same size of medium was picked up with an inoculation shovel and dispersed, and then inoculated into 14 different fermentation media. cultured in a shaker at 28° C. and 200 rpm.

Selection of Fermentation Time

[0113] The fermentation broth samples of the above-mentioned different media were collected after growing for 3 days, 5 days, 7 days and 10 days, respectively, and the supernatant was collected after centrifugation to measure the antivirus activity.

2. Determination of Antivirus Activity of the Fermentation Samples

[0114] The determination of antivirus activity was completed by CAMS Key Laboratory of Antiviral Drug Research, Institute of Medicinal Biotechnology, Chinese Academy of Medical Sciences & Peking Union Medical College, and the virus strains were influenza virus A/ Fort Monmouth/1/47 (H1N1) and A/wuhan/359/95 (H3N2).

[0115] Steps of the antiviral assay: [0116] (1) Use a 96-well plate to inoculate Madin-Darby canine kidney cells (MDCK), and cells seeded in plates at 37 C with 5% CO.sub.2, [0117] (2) After 24 hours, the cells were infected with influenza virus for 2 hours, followed by treatment with the test samples and active drugs for 48 or 72 h to set up cell control wells and virus control wells, and continue to culture, [0118] (3) The 50% inhibitory concentration (IC50) was determined by the Reed and Muench method, The 50% toxicity concentration (TC50) of the test samples and positive compounds was also evaluated by the CPE assay. The selectivity index (SI) was calculated as the ratio of TC50/IC50.

[0119] The results of the antiviral assay showed that the fermentation broth sample from A3 medium had the highest antiviral A/wuhan/359/95 (H3N2) activity, followed by A1 fermentation medium and A2 fermentation medium. The fermentation broth samples at 5 days were significantly higher than the other 3 time points (shown in Table 1). In addition, according to the growth of the strain and the results of the antiviral assay, B7 was selected as an inactive fermentation medium as a negative control for subsequent comparative transcriptome analysis to help the screening of target biosynthetic gene clusters.

[0120] Further research showed that the fermentation broth of Streptomyces sp. CPCC 200451 from A3 medium not only had good activity against influenza virus A/wuhan/359/95 (H3N2), but also had good activity against influenza virus A/FM/1/47 (H1N1) (shown in Table 2).

TABLE-US-00005 Antiviral activity of the fermentation crude extract from Streptomyces sp. CPCC 200451. Dose TC.sub.50 A/wuhan/359/95(H3N2) Fermentation media Fermentation time (.Math.g/mL or Dilution ratio) (.Math.g/mL or Dilution ratio) IC.sub.50 (.Math.g/mL or Dilution ratio) SI A1 3d fermentation broth⅒ 53/10000 713/1000000 7.4 A2 3d fermentation broth⅒ >⅒ 693/10000 >1.4 A3 3d fermentation broth⅒ >⅒ 16/10000 >62.5 A1 5d fermentation broth⅒ >⅒ 333/10000 >3.0 A2 5d fermentation broth⅒ >⅒ 333/10000 2.1 A3 5d fermentation broth⅒ >⅒ 4/10000 >250 A1 7d fermentation broth⅒ >⅒ 192/10000 >5.2 A2 7d fermentation broth⅒ 12/10000 2/10000 6.0 A3 7d fermentation broth⅒ >⅒ 21/10000 >47.6 A1 10d fermentation broth⅒ >⅒ 11/1000 >9.1 A2 10d fermentation broth⅒ 9/10000 3/10000 3.0 A3 10d fermentation broth⅒ >⅒ 12/10000 >83.3 Oseltamivir 200 1260 1.63 773

TABLE-US-00006 Antiviral activity of the fermentation crude extract from Streptomyces sp. CPCC 200451. Dose (.Math.g/mL or Dilution ratio) TC.sub.50 (.Math.g/mL or Dilution ratio) A/wuhan/359/95(H3N2) A/Fort Monmouth/1/47(H1N1) Sample information# IC.sub.50 (.Math.g/mL or Dilution ratio) SI IC.sub.50 (.Math.g/mL or Dilution ratio) SI A3-3d stock solution⅒ >⅒ 9/100000 >1111.1 8/10000 >125.0 A3-5d stock solution⅒ >⅒ 7/100000 >1428.6 32/10000 >32.3 Oseltamivir 200 1260 1.63 773.0 2.01 626.9 RBV 200 1164.1 1.63 773.0 0.82 1419.6

3. Comparative Transcriptome Analysis and Real-time Quantitative PCR (RT-qPCR) Assay

[0121] According to the antiviral assay, A3 and B7 were selected as highly active and inactive fermentation media, respectively. to perform transcriptome sequencing (RNA-seq) and data analysis.

Extraction of RNA Samples

[0122] According to the results of the antiviral assay of the fermentation broth, A3 and B7 were selected as highly active and inactive fermentation media, respectively. The mycelia and fermentation supernatants from these two media at the early stages (12 h, 24 h, 48 h) of fermentation were collected. The improved TRIzol method was used to extract the total RNA of Streptomyces CPCC 200451, and the sample names were A3-24, A3-48, A3-72, B7-24, B7-48 and B7-72.

[0123] After testing, there were 6 samples of the RNA extraction with good quality, and there was no obvious genomic DNA contamination and serious degradation, which basically met the requirements of high-throughput sequencing.

RNA Transcriptome Sequencing and Data Analysis

[0124] RNA-sequencing (RNA-seq) was performed by the BGI (China), using the second-generation sequencing platform BGISEQ-500. the results were visualized to analyze the genome-wide transcription levels as shown in FIG. 1. In conjunction with the information of 38 secondary metabolite BGCs predicted by antiSMASH, three BGCs-namely, clusters 27, 28 and 36-showed significantly higher transcription levels under the A3 fermentation condition.

[0125] The first differentially expressed gene cluster is Cluster 27, which is an NRPS-type biosynthetic gene cluster for the production of siderophore, the results of transcription were visualized as shown in FIG. 2, It can be seen that, compared with the B7 inactive fermentation medium, Cluster 27 showed significantly high expression in the A3 highly active fermentation medium.

[0126] Cluster 28 is also biosynthetic gene clusters of siderophore. the results of transcription were visualized as shown in FIG. 3, It can be seen that, compared with the B7 inactive fermentation medium, Cluster 28 showed significantly high expression in the A3 highly active fermentation medium.

[0127] The third gene cluster showing significant differences at the transcriptional level is Cluster 36, which is an NRPS-type biosynthetic gene cluster that exhibits significantly high expression in A3 highly active fermentation medium. the results of transcription were visualized as shown in FIG. 4.

Transcriptomics Analysis by RT-qPCR Assay

[0128] The transcriptomic results were further verified by RT-qPCR.

[0129] Based on bioinformatic analysis, both clusters 27 and 28 were found to be BGCs for the production of siderophores, three key genes in Cluster 27 were selected, namely C27_5814 (dhb), C27_5819 (NRPS), C27_5821 (transporter), and three key genes in Cluster 28 were selected, namely C28- 5949 (IucA_IucC), C28-5950 (transporter) and C28-5951 (ATP-grasp), Also, three functional genes, C36_7094 gene (NRPS), C36_7097 gene (NRPS) and C36_7098 gene (NRPS) in the Cluster 36 biosynthetic gene cluster were selected. the genes were subjected to RT-qPCR assay, respectively. The results are shown in FIG. 4, FIG. 5, and FIG. 7. The RT-qPCR verification results were consistent with the transcriptome sequencing results, indicating that the transcriptome sequencing data were credible.

Example 3. Bioinformatics Analysis and Functional Analysis of Three Key Gene Clusters

[0130] Based on bioinformatic analysis, both clusters 27 and 28 were found to be BGCs for the production of siderophores, as the presence of iron box sequences in the cluster, which were closely regulated by a class of repressors in Streptomyces, sensed the presence of Fe3.sup.+.

[0131] Therefore, we added 0.05% iron ions to the A3 highly active fermentation medium, namely A3-Fe.sup.3+ fermentation medium. Streptomyces sp. CPCC 200451 was fermented and cultured under the same conditions using both A3 and A3-Fe.sup.3+ media. The mycelia and fermentation supernatants from these two media at the early stages (48h) of fermentation were collected for RNA extraction, and then, RNA-Seq sequencing, data analysis, and RT-qPCR verification were performed, the transcriptome analysis demonstrated that clusters 27 and 28 were shut down after adding a sufficient amount of Fe3+ (0.05% final concentration) to the A3 fermentation medium, while cluster 36 was still highly expressed (FIG. 8). RT-qPCR was used to verify that the expression of Cluster 36 in A3 and A3-Fe.sup.3+ medium was significantly higher than that in A1 medium, which was consistent with the transcriptome comparison results (FIG. 9). Combined with the activity assay which showed that Streptomyces sp. CPCC 200451 fermentation broth in the presence of Fe.sup.3+ still exhibited a similar level of anti-IAV activity, Thus, we speculated that cluster 36 was the BGC responsible for the biosynthesis of antiviral active compounds in Streptomyces sp. CPCC 200451.

[0132] Cluster 36 is located in the genome chromosome 1: 7,822,964-7,875,615 of Streptomyces sp. CPCC 200451, with a full length of 52.6 kb. Bioinformatics analysis predicts that the gene cluster contains a total of 50 open reading frames (ORFs). The core region of the gene cluster is genes 7092-7102 (chromosome 1: 7,841,516-7,857,514).

[0133] The amino acid sequences of the proteins encoded by the 50 open reading frames contained in Cluster 36 were analyzed for homology using the BLASTP function in the GenBank database. The results showed that Cluster 36 belonged to the NRPS biosynthetic gene clusters, NRPS (Nonribosomal peptide synthetases) plays a key role in the synthesis of non-ribosomal polypeptides. It is a multifunctional protein complex composed of multiple independent modules connected in a specific spatial order. It can specifically recognize, activate and transport specific amino acid substrates which are condensed in a certain order to form peptide chains, and then, non-ribosomal polypeptides are synthesized and released. Each module in NRPS contains at least three core domains, including the adenylation domain (A domain), the peptidyl carrier protein domain (PCP domain), and the condensation domain (C domain). The last component of NRPS also contains a special domain, which is the most downstream of the synthetase peptide chain, called the thioesterase domain (TE domain), which is responsible for releasing the peptide chain from the NRPS module. In addition, other specific domains may also be included, such as epimerization domain (Epimerization, E domain), methylation domain (Methyltransferase, M domain), etc.

[0134] The biosynthetic gene clusters of Cluster 36 and Deimino-antipain have the highest similarity of 66% predicted by antiSMASH, and the similar genes are located in the core region of Cluster 36. The protein sequences encoded by the similar genes in Cluster 36 and Deimino-antipain are using BLASTP tool for comparison, the results are shown in FIG. 10. This family of protease inhibitors have been found for 40 years, they typically feature relatively low molecular weight, hydrophobicity, the presence of C-terminal aldehydes, and internal ureido linkages, and the high structural similarity suggests that they share a common biosynthesis Pathways, therefore, they have evolved to form clusters of related biosynthetic genes.

[0135] In 2016, Maxson et al. obtained Deimino-antipain from Streptomyces albulus NRRL B-3066 by a chemical reactivity-based screening, and analyzed its biosynthetic gene clusters. as shown in FIG. 11. Its BGCs are composed of the gene anpC-G NRPS, in which the A domains of the genes anpD, anpE, and anpF are responsible for the assembly of Arginine, Phenylalanine, and Valine, respectively. However, as for the fourth A domain responsible for the assembly of Arg (or Cit), one speculation is that the Phe loading module (anpE) also installs Arg/Cit, Which is similar to the biosynthesis of syringolin or the Arg specific module (anpD) in a discontinuous manner way to perform the function twice, the other case is that anpD installs Cit (or Arg is subsequently replaced by Cit) followed by Arg in a specific, non-consecutive way. The gene anpC contains the C domain only, whereas the gene anpG contains the PCP and C domains, as well as the NAD reduction (R) domain that may be responsible for the release, ultimately producing the C-terminal aldehydes. In addition, the anpA gene may encode hydrolases, which may act before or after the assembly of Arginine and play a role in the formation of Cit. The gene anpB belongs to the MFS (major facilitator superfamily) transporter superfamily, and the encoded product of anpH is histidine kinases. Subsequently, Maxson et al. demonstrated that the assembly of Cit in Deimino-antipain requires other genes by using heterologous expression.

[0136] As reported in the literatures, according to the presence of the gene anpI encoding acyl-CoA dehydrogenase and its arrangement position, when the direction and sequence of the anpB-G genes are consistent, the biosynthetic gene clusters responsible for the synthesis of such peptide aldehyde compounds roughly divided into three categories: the first category is the biosynthetic gene cluster that does not contain the gene anpI, such as Deimino-antipain, the second category is that the gene anpI is located between anpD and anpE which accounts for the majority, and only a few gene clusters have anpI located after the gene anpG, which is the third category. Therefore, Cluster 36 in Streptomyces sp. CPCC 200451 belongs to the second category. Moreover, there is an additional gene encoding SDR reductase in the gene Cluster 36, and its function needs further research.

[0137] In summary, we can speculate that the products of Cluster 36 encoded in Streptomyces sp. CPCC 200451 are rich and diverse, and the products may be structurally similar to compounds such as Deimino-antipain, chymostatin, elastatinal and MAPI. In order to further confirm whether Cluster 36 is the biosynthetic gene cluster where the antiviral components of Streptomyces CPCC 200451 are located, knockout and overexpression of genes in this strain were performed.

Example 4. Gene Knockout Method to Verify the Function of Cluster 36 Gene Cluster in Streptomyces CPCC 200451

[0138] When CPCC 200451 was cultured in MS medium for 96-120 h, the morphology and number of spores reached the optimum state, and 120 h was selected as the spore collection time of CPCC 200451. Meanwhile, since CPCC 200451 is sensitive to apramycin, apramycin was selected as the selection marker of CPCC 200451, and Aztreonam was selected as the inhibitor of E. coli in the conjugation transfer experiment.

[0139] Establishment of CPCC 200451 Knockout Genetic Operating System:

[0140] Two NRPS-type functional genes gene 7094 (Cromosome 1: 7,844,718-7,847,825) and gene 7098 (Cromosome 1: 7,850,958-7,852,772) in Cluster 36 were selected to construct a knockout genetic operating system, respectively.

[0141] Design primers to amplify two fragments (i.e., forearm and rear arm) containing the upstream and downstream of the target genes respectively, connect them to the multiple cloning site of the suicide plasmid pOJ260, and introduce the recombinant plasmid into Streptomyces sp. CPCC 200451 by conjugation transfer. Single-crossover strains were screened using apramycin resistance marker. And then, single-crossover strains were subculture on MS solid medium without apramycin for about 5 generations, to screened for double-crossover mutant strains who lost apramycin resistance, and the results are verified by PCR technology, a blocker strain that lacks the target gene is obtained finally. The steps are as follows.

Construction of Blocking Plasmid

[0142] Using CPCC 200451 genomic DNA as a template, two pairs of primers were designed at about 2000 bp on the left and right sides of the 7094 gene and the 7098 gene, respectively,

[0143] and the left and right homology arms for double crossover were amplified by PCR technology. The lengths of the two arms of the 7094 gene were 2129 bp and 2215 bp, respectively, the lengths of the two arms of the 7098 gene were 2056 bp and 2173 bp, respectively. HindIII and EcoRI restriction sites were introduced at both ends of the left arm, and EcoRI and HindIII restriction sites were introduced at both ends of the right arm, respectively.

[0144] The pOJ260 suicide plasmid was selected for the construction of the blocking strain. First, the left and right homology arms obtained by PCR amplification were respectively connected to the T vector and transformed into E.coli competent cells. The recombinant plasmid was extracted for sequencing verification. and the qualified plasmid was digested with EcoRIand HindIII, the plasmid pOJ260 was digested with HindIII at the same time, and after the large fragment of the vector DNA was recovered, three fragments were ligated with the above-mentioned left and right homology arms that had been digested, and the ligated product was transformed into E. coli DH5α competent cells, The positive transformants were screened by the apramycin resistance marker located in the plasmid pOJ260 and the plasmids were extracted and verified by enzyme digestion (FIG. 12 and FIG. 13) to obtain the correct recombinant plasmids, which were named pOJ7094LR and pOJ7098LR respectively.

[0145] Lanes 1-3, pOJ7094LR/HindIII, lanes 4-6, pOJ7094LR/EcoRI, lanes 7-9, pOJ7094LR/PstI, lanes 10-12, pOJ7094LR/KpnI.

[0146] Lanes 1-3, pOJ7098LR/HindIII, lanes 4-6, pOJ7098LR/EcoRI, lanes 7-9, pOJ7098LR/PstI, lanes 10-12, pOJ7098LR/NcoI.

Screening of Single-Crossover Mutants

[0147] The recombinant plasmids pOJ7094LR and pOJ7098LR were transformed into E. coli ET12567/pUZ8002 competent cells, and then introduced into CPCC 200451 by conjugative transfer, apramycin and aztreonam were used for resistance screening. 3-5 days later, the conjugation with apramycin resistance grew on the plate, and a single colony was picked and copied to the plate containing apramycin, which was a possible single-crossover mutant.

[0148] The single-crossover mutants were identified by PCR technology by extracting the total genomic DNA of the strains. Three pairs of primers (P1P2, P3P4 and P5P6) were designed to amplify the left homology arm and its flanking region, the right homology arm and its flanking region, and fragments of the target gene respectively (FIG. 14).

[0149] In the case of a left single crossover mutant, when PCR is performed using primer P1P2, the left homology arm except for the product fragment size of about 2 kb can be amplified. On the contrary, when using primer P3P4 to amplify the right homology arm with a product fragment size of about 2 kb, it is a right single-crossover strain.

Screening of Double-Crossover Mutants

[0150] The qualified single-crossover strains verified by PCR were subcultured on MS solid medium without apramycin for about 5 generations, and the strains that lost apramycin resistance were screened by photocopying, and the double-crossover mutants were identified by PCR technology. When using the P3 primer located on the right edge of the left homology arm and the P2 primer located on the left edge of the right arm for PCR verification, only a small fragment of the target band can be amplified, but the fragment of the gene as long as the knockout gene cannot be amplified. the internal fragment of the gene cannot be amplified by using P5P6 primer, and the primer P1P4 can amplify the ligation product of the left homology arm and the right homology arm of about 4kb, and the 4kb PCR product is sequenced to verify, if the sequence of the left and right homology arms is correct, which proves that the strain is a double-crossover mutant.

[0151] A total of 12 single-crossover zygotes of gene 7094 were obtained, and then, one left single-crossover and one right single-crossover mutant were selected to subculture for 5 generations on MS plates without apramycin, the spores were collected for dilution and coating plate. two double-crossover mutants (named 7094-KO-10 and 7094-KO-33) were screened from the right single-crossover mutants, and verified by PCR, as shown in FIG. 15.

[0152] The 7098 gene was screened on a plate containing apramycin resistance, and only one zygote was obtained, which was verified by PCR. Similarly, after subculturing this strain on MS plates without apramycin for 5 generations, we screened for double-crossover mutants that lost apramycin resistance (named 7098-KO-37 and 7098- KO-47), and PCR identification was performed, as shown in FIG. 16.

Validation of Blocking Strains by RT-qPCR

[0153] The blocking strains 7094-KO, 7098-KO and CPCC 200451 wild-type strains obtained by the above screening were fermented under the same conditions using A3-Fe.sup.3+ medium with excess iron ions. the mycelia were collected at the early stages of fermentation (48 h) and RNA was extracted, after reverse transcribing into cDNA, RT-qPCR was performed to verify the related genes of Cluster 36 (FIGS. 17 and 18). The results showed that the target gene had been successfully knocked out, at the same time, it was also found that when the 7094 gene was knocked out, the 7098 gene was no longer expressed, and the expression of the 7097 gene and the 7099 gene was also affected, and after the 7098 gene was knocked out, the 7094 Gene expression was not affected.

Construction of Complementary Strains

[0154] Using the genomic DNA of wild-type Streptomyces sp. CPCC 200451 as the template, primers 7094_F (containing NdeI restriction site), 7094_R (containing XbaI restriction site), 7098_F (containing NdeI restriction site) and 7098_R (containing NdeI restriction site) were designed respectively. The 7094 gene and the 7098 gene were amplified by PCR technology and cloned into the pSET152 plasmid (containing a strong erythromycin promoter and phage ΦC31 integration site, with apramycin resistance), 7094 gene and 7098 gene genetically complementary recombinant plasmids were constructed respectively on the corresponding restriction sites. After verification by enzyme digestion and sequencing, the complementary plasmids pL-7094 and pL-7098 were obtained.

[0155] The correct complementing plasmids were introduced into the blocking strains 7094-KO and 7098-KO by conjugation transfer, and the apramycin resistance of the plasmid pSET152 was used as the selection marker, and three zygotes were selected for each gene to be verified by PCR technology using 3 pairs of primers including apramycin resistance, pSET152 integration site and apoplexy gene. The results showed that the genetically complementary strains 7094-KOC and 7098-KOC were successfully constructed.

Validation of Strains by RT-qPCR

[0156] The blocking strains 7094-KO and 7098-KO obtained, the complementary strains 7094-KOC, 7098-KOC and the Streptomyces sp. CPCC 200451 wild-type strain were simultaneously fermented under the same conditions using A3-Fe3+ fermentation medium.

[0157] the mycelia were collected at the early stages of fermentation (48 h) and RNA was extracted, after reverse transcribing into cDNA, RT-qPCR was performed to verify the related genes. The results showed that the 7094 gene was successfully complemented into the knockout strain 7094-KO, the 7098 gene was successfully complemented into the blocker strain 7098-KO.

Determination of Anti-Influenza Virus Activity of Blocking Strains and Complementary Strains

[0158] The anti-influenza virus activity of the fermentation broths of the blocking strains 7094-KO, 7098-KO, the complementing strains 7094-KOC, 7098-KOC and the CPCC 200451 wild-type strains was tested.

[0159] The results showed that knockout of the gene 7094 Or complementation of this gene, the anti-influenza virus activity of Streptomyces CPCC 200451 disappeared, while inactivation of gene 7098 led to a loss of anti-influenza virus activity, and complementation of this gene could restore the antiviral activity (Table 3). Therefore, it was proved that the expression of Cluster 36 was closely related to the anti-influenza virus activity of Streptomyces sp. CPCC 200451.

TABLE-US-00007 Determination of the anti-influenza virus activity of the fermentation samples of the strains WT, blocking strain, and complementing strain cultured by A3 + Fe.sup.3+ medium. Sample information Dose (.Math.g/mL or dilution ratio) TC.sub.50 (.Math.g/mL or dilution ratio) A/Wuhan/359/1995 (H3N2) IC.sub.50 (.Math.g/mL or dilution ratio) SI 200451-WT stock solution⅒ >⅒ 16/10000 >62.5 7094-KO-10 stock solution⅒ >⅒ >1/30 - 7094-KO-33 stock solution⅒ >⅒ >1/30 - 7094-KOC-1 stock solution⅒ >⅒ >⅒ - 7094-KOC-2 stock solution⅒ >⅒ >⅒ - 7094-KOC-3 stock solution⅒ >⅒ >⅒ - 7098-KO-37 stock solution⅒ >⅒ 33/1000 >3.0 7098-KO-47 stock solution⅒ >⅒ >1/30 - 7098-KOC-1 stock solution⅒ >⅒ 26/10000 >38.5 7098-KOC-2 stock solution⅒ >⅒ 48/10000 >20.8 7098-KOC-3 stock solution⅒ >⅒ 37/10000 >27.0 Oseltamivir 1000 577.4 2.01 287.3

Example 5. Establishment of Overexpression Genetic Operating System

[0160] To further confirm the role of cluster 36 in the biosynthesis of the antiviral metabolites in Streptomyces sp. CPCC 200451, we selected 5 regulatory genes in this gene cluster, constructed overexpression plasmids based on plasmid pSET152 and introduced them into Streptomyces sp. CPCC 200451. The recombinant strains were fermented under the same conditions using A1 fermentation medium, and by detecting and comparing the changes in anti-influenza virus activity, the regulatory genes and their regulatory effects on the expression of anti-influenza active ingredients in Cluster 36 were determined.

1. Construction of Regulatory Gene Overexpression Plasmid

[0161] First, using the genomic DNA of Streptomyces sp. CPCC 200451 as a template, five regulatory genes 7081, 7082, 7083, 7089 and 7102 in Cluster 36 were selected, and primers were designed respectively to amplify the DNA fragments of these five regulatory genes by using PCR technology.

[0162] The integrated plasmid pSET152 was digested with NdeI and BamHI. Since the regulatory genes 7081 and 7089 contain BamHI sites, NdeI and XbaI sites were introduced at their two ends respectively. The plasmid pSET152 was digested with NdeI and XbaI at the same time. NdeI and BamHIrestriction sites were introduced into both ends of 7082, 7083 and 7102 regulatory genes.

[0163] the PCR product was ligated to the pEASY-T vector, and after sequencing to verify that the sequence was correct, the regulatory gene was digested with the corresponding restriction site and the product was recovered, and then it was connected to the plasmid pSET152 vector after the same restriction enzyme digestion. to obtain recombinant plasmids.

2. Introducing the Recombinant Plasmids Into Streptomyces Spp. CPCC 200451 By Electrotransformation

[0164] The above recombinant plasmids were introduced into Streptomyces sp. CPCC 200451 wild-type strain by electrotransformation, and screened by apramycin resistance to obtain overexpressed recombinant strains. At the same time, the empty vector pSET152 was introduced into the wild-type strain of Streptomyces sp. CPCC 200451 as a control. The primers for PCR verification are pSET152 and attB-Streptomyces. If the recombinant plasmid is correctly integrated into the genome of Streptomyces sp. CPCC 200451, the target band of 1.6kb can be amplified by PCR. The result showed that regulated gene 7081, 7082, 7083 and 7102 obtained 3 overexpressing strains respectively, regulated gene 7089 obtained 2 recombinant strains, named 200451/pL-7081, 200451/pL-7082, 200451/pL-7083, 200451/pL-7089 and 200451/pL-7102 respectively.

3. Determination of Anti-Influenza Virus Activity of Overexpressed Strains

[0165] In order to further explore the effect of up-regulation of regulatory genes in Cluster 36 on the anti-influenza virus activity of Streptomyces sp. CPCC 200451, three fermentation media, A1, A3 and B7, were selected to ferment the overexpressed strains on the same conditions. and the fermentation broth samples were collected for the determination of anti-influenza virus activity (Table 4). The results showed that when the regulatory gene 7102 was overexpressed, the anti-influenza virus activity of the fermentation samples from A1 and A3 medium showed a certain degree of improvement, after overexpressing the other four regulatory genes, the antiviral activity of the fermentation broth was not obvious. In addition, the fermentation products using B7 medium did not show significantly improved anti-influenza virus activity, mainly because B7 is an oligotrophic medium, and the growth of streptomyces is restricted to synthesize abundant secondary grade metabolites.

TABLE-US-00008 Determination of anti-influenza virus activity of overexpressed strains Strain information Fermentation media Dose (.Math.g/mL or dilution ratio) TC.sub.50 (.Math.g/mL or dilution ratio) A/Wuhan/359/1995 (H3N2) IC.sub.50 (.Math.g/mL or dilution ratio) SI 200451-WT A1 stock solution⅒ >⅒ 104/10000 >9.6 200451/pL-7102 A1 stock solution⅒ >⅒ 39/10000 >25.6 200451-WT A3 stock solution⅒ >⅒ 21/10000 >47.6 200451/pL-7102 A3 stock solution⅒ >⅒ 6/10000 >166.8 200451-WT B7 stock solution⅒ >⅒ >⅒ - 200451/pL-7102 B7 stock solution⅒ >⅒ 50/1000 >2.0 Oseltamivir 1000 >1000 1.77 >565.0

4. Transcriptome Analysis of Overexpression Strains

[0166] he overexpression of gene 7102 caused an increase in the anti-IAV activity of the fermentation samples of A1 medium, we conducted a further study on the difference in the transcription level of this change. the wild-type (WT) strain and gene 7102 overexpression strain were simultaneously fermented by using A1 fermentation medium, and the mycelia were collected at the early stages of fermentation (48 h) and RNA was extracted to perform transcriptome sequencing (RNA-Seq) and data analysis. The transcription of Cluster 36 was visualized using a visualization tool (FIG. 19). The results showed that the genes in the core region of Cluster 36 (Chromosome 1: 7,841,516-7,858,166) were significantly up-regulated after the overexpression of the regulatory gene 7102.

5. Validation of Overexpression Strains by RT-qPCR

[0167] In order to verify the reliability of the transcriptome data, we also reverse transcribed the extracted RNA samples into cDNA for quantitative RT-qPCR verification. The results are shown in FIG. 20. Compared with the wild-type strain of Streptomyces sp. CPCC 200451, the mycelia collected from the A1 fermentation medium overexpressed the regulatory gene 7102, and the genes in the core region of Cluster 36 showed a 2-8-fold increase. This change is consistent with the transcriptome results.

[0168] Therefore, we infer that the regulatory gene 7102 regulates the expression of genes in the core region of Cluster 36, and the up-regulation of gene 7102 will cause the increase of the anti-influenza virus activity of Streptomyces sp. CPCC 200451, that is, The positive regulatory function of the genes 7102 is confirmed.

[0169] To sum up, this study selected two functional genes and constructed knockout genetic operating systems (7098-ko, 7094-ko). The results of RT-qPCR verification showed that the two functional genes were successfully knocked out, and the knockout strains and wild-type of Streptomyces CPCC 200451 were fermented and tested for their anti-influenza virus activity. The results showed that inactivation of the functional genes led to a loss of anti-influenza virus activity. we also performed overexpression of multiple regulatory genes situated in this cluster. The five regulatory genes-namely, 7081 (TetR family), 7082 (streptomyces antibiotic regulatory protein (SARP) family), 7083 (ArsR family), 7089 (LysR family), and 7102 (TetR family) were selected, the results revealed that only the overexpression of gene 7102 caused an increase in the anti-IAV activity. The gene expression changes of cluster 36 between the wild-type (WT) strain and gene 7102 overexpression strain shown by the RNA-seq data suggested that overexpression of gene 7102 did indeed cause a significant up-regulation of the genes in the NRPS core region of cluster 36. This finding was confirmed by qRT-PCR. Therefore, cluster 36 was the BGC responsible for the biosynthesis of antiviral active compounds in Streptomyces sp. CPCC 200451.

Example 6. Chemical Separation and Purification of Antiviral Components

[0170] It showed that adding excess iron ions to A3 highly active medium can make the biosynthesis gene cluster of siderophore no longer expressed while Cluster 36 can be highly expressed in the preliminary experiments. Therefore, the Streptomyces sp. CPCC 200451 strain was fermented in large quantities by using A3-Fe.sup.3+ medium, At the same time, the knockout mutants 7098-KO and 7094-KO as a negative control was fermented under the same conditions, and the supernatant of the fermentation was collected by centrifugation. Guided by the results of HPLC analysis and antiviral assay, the components with anti-influenza virus activity were traced, and the samples were prepared and purified by HPLC. The separation process of active compounds is shown in FIG. 21.

[0171] The fermentation broth of the wild-type stain of Streptomyces sp. CPCC 200451 was centrifuged to collect a total of 14 L of the supernatant, The supernatant was adsorbed by microporous adsorption resin (Diaion HP20, Mitsubishi, Japan). The column was then rinsed with twice the column volume of deionized water. Gradient elution was carried out with 20%, 50%, and 100% ethanol-water (v/v), respectively. Each gradient was eluted until the effluent had no color and designated as crude extracts 20E, 50E, and 100E, respectively. The eluates of each gradient were separately collected, condensed by evaporation and lyophilized to determine their anti-influenza virus activity, The results showed that the antiviral active components were mainly concentrated in 50E elution, in addition, the 100E eluted fraction also had some activity (Table 5).

TABLE-US-00009 The results of anti-influenza virus activity assay Sample NO. Dose (.Math.g/mL or dilution ratio) TC.sub.50 (.Math.g/mL or dilution ratio) A/Wuhan/359/1995 (H3N2) IC.sub.50 (.Math.g/mL or dilution ratio) SI 200451 stock solution 577/10000 21/10000 27.5 200451-unadsorbed fraction stock solution⅒ >⅒ >1/30 - 200451-water eluent stock solution⅒ >⅒ >1/30 - 200451-20E 500 >500 >500 - 200451-50E 500 >500 10.69 >46.8 200451-100E 500 >500 23.86 >21.0 7098-KO stock solution⅒ ⅒ >⅒ - 7094-KO-20E 500 >500 >166.67 - 7094-KO-50E 500 >500 >166.67 - 7094-KO-100E 500 288.68 166.67 1.7 7098-KO stock solution⅒ 577/10000 33/1000 1.7 7098-KO-20E 500 >500 >500 - 7098-KO-50E 500 >500 >500 - 7098-KO-100E 500 288.68 >166.67 - Oseltamivir Phosphate 1000 577.35 2.01 287.3 RBV 1000 >1000 2.47 >404.9

[0172] The 50E eluent with the best anti-influenza virus activity obtained was concentrated and then Octadecylsilyl silica gel (ODS-A-HG, YMC, Japan) was used for the open column chromatography to conduct further separation. Gradient elution was carried out with 10%, 12%, 15%, 20%, 25%, 30%, 40%, 50%, 80% and 100% acetonitrile-water (v/v), each elution were analyzed by HPLC using an Agilent-C18-Aq analytical column (5 .Math.m, 4.6 × 150 mm) with acetonitrile and water (containing 0.1% TFA) as mobile phase, analysis conditions are 0-30 min (0-30% acetonitrile), 30-60 min (30-100% acetonitrile). According to the HPLC analysis results of the main components in each fraction, a total of 10 components (A-J) were obtained after merging, which were expressed as 50E-C18-A~J, respectively, the 10 components were tested for anti-influenza virus activity (shown in Table 6). The results showed that the 50E-C18-C~I components all had certain anti-influenza virus activity, and the antiviral activities of the 50E-C18-E and 50E-C18-F components were significantly higher than those of the other components.

TABLE-US-00010 Determination of anti-influenza virus activity of components in 50E-C18 Sample information Dose (.Math.g/mL or dilution ratio) TC50 (.Math.g/mL or dilution ratio) A/Wuhan/359/1995 (H3N2) IC.sub.50 (.Math.g/mL or dilution ratio) SI 50E-C18-A 500 >500 >500 - 50E-C18-B 250 >250 44.92 >5.6 50E-C18-C 500 >500 6.17 >81.0 50E-C18-D 250 >250 4.99 >50.1 50E-C18-E 500 >500 2.06 >242.7 50E-C18-F 500 >500 4.09 >122.2 50E-C18-G 500 >500 12.35 >40.5 50E-C18-H 500 >500 166.67 >3.0 50E-C18-I 250 >250 12.19 >20.5 50E-C18-J stock solution⅒ >⅒ 84/10000 >11.9 Oseltamivir 1000 577.35 2.47 233.7 RBV 1000 >1000 2.47 >404.9

Example 7. Isolation and Structural Identification of Secondary Metabolites

[0173] Omicsynin A was isolated from 50E-C18-G component by RP-HPLC (SHISEIDO Capcell-Pak PFP 5 .Math.m, 10 × 250 mm, 25% ACN/H2O containing 0.1% TFA, 1.5 mL/min),

[0174] The components 50E-C18-E and 50E-C18-F were directly semi-prepared by RP-HPLC (SHISEIDO Capcell-Pak PFP 5 .Math.m, 10 × 250 mm, 20% ACN/H2O with 0.1% HCOOH, 1.5 mL/min) to obtain a group of compounds, named Omicynin B.

[0175] The component 200451-100E was directly semi-prepared by RP-HPLC (SHISEIDO Capcell-Pak PFP 5 .Math.m, 10×250 mm, 40% ACN/H2O containing 0.1% TFA, 1.5 mL/min) to obtain a group of compounds, named as Omicsynin C.

[0176] the chemical structures of the compounds were deduced by analysis of spectroscopic data including HRESIMS, .sup.1H-NMR, .sup.13C-NMR, DEPT, 1H-1H COSY, HSQC, HMBC and NOESY. as shown in Table 7 below.

TABLE-US-00011 Structure identification of Omichin A-C Description Structural Formula Structural Identification Omicsynin A1 [00046] NMR HRMS Omicsynin A2 [00047] NMR HRMS Omicsynin A3 (Chymostatinol A) [00048] NMR HRMS Omicsynin A4 [00049] NMR HRMS Omicsynin A5 (Chymostatinol B or C) [R═CH(CH.sub.3)CH.sub.2CH.sub.3 or CH.sub.2CH(CH.sub.3).sub.2] [00050] HRMS Omicsynin A6 [R═CH(CH.sub.3)CH.sub.2CH.sub.3 or CH.sub.2CH(CH.sub.3).sub.2] [00051] HRMS Omicsynin B1 [00052] HRMS Omicsynin B2 [00053] HRMS Omicsynin B3 [00054] HRMS Omicsynin B4 (Antipain) [00055] HRMS Omicsynin B5 [R═CH(CH.sub.3)CH.sub.2CH.sub.3 or CH.sub.2CH(CH.sub.3).sub.2] [00056] HRMS Omicsynin B6 [R═CH(CH.sub.3)CH.sub.2CH.sub.3 or CH.sub.2CH(CH.sub.3).sub.2] [00057] HRMS Omicsynin C1 [00058] HRMS Omicsynin C2 [00059] HRMS Omicsynin C3 (Chymostatin B) [00060] HRMS Omicsynin C4 [00061] HRMS Omicsynin C5 (Chymostatin A or C) [R═CH.sub.2CH(CH.sub.3).sub.2 or CH(CH.sub.3)CH.sub.2CH.sub.3] [00062] HRMS Omicsynin C6 [R═CH.sub.2CH(CH.sub.3).sub.2 or CH(CH.sub.3)CH.sub.2CH.sub.3] [00063] HRMS

[0177] Omicsynin A1 and Omicsynin A2 are new compounds as shown in FIG. 22, and the NMR data are shown in Table 8. Data of 1H-NMR, 13C-NMR, DEPT, 1H-1H COSY, HSQC, HMBC, NOESY spectra and HRMS analysis data are shown in FIGS. 23 and 24.

[0178] The absolute configuration of Omicsynin A1 and Omicsynin A2 was determined by Marfey method, as shown in FIG. 25.

[0179] The HRMS analysis data of compounds A6, B1, B2, B3, B5, B6, C1, C2, C6 are shown in FIGS. 26~34.

TABLE-US-00012 NMR data of compounds Omicsynin A1 and Omicsynin A2 (600 MHz, DMSO-d6) Omicsynin A1 Omicsynin A2 No. δ.sub.H δ.sub.C,type No. δ.sub.H δ.sub.C,type 1 173.5, C 1 173.8, C 2 4.28, m 54.2, CH 2 4.30, m 54.1, CH 3 3.01, dd (13.8, 6.0) 37.5, CH.sub.2 3 2.98, dd 37.5, CH.sub.2 2.86, dd (13.8, 5.4) 2.86, dd 4 137.4, C 4 137.4, C 5 7.16, ov.sup.b 129.2, CH 5 7.16, ov.sup.b. 129.1, CH 6 7.23, ov 128.1, CH 6 7.22, ov 128.0, CH 7 7.16, ov 126.4, CH 7 7.16, ov 126.3, CH 8 7.23, ov 128.1, CH 8 7.22, ov 128.0, CH 9 7.16, ov 129.2, CH 9 7.16, ov 129.1, CH NH 6.46, d (7.8) NH 6.32 10 157.3, C 10 157.2, C 11 4.36, br t (7.8) 54.5, CH 11 4.11, m 52.4, CH 12 3.46, m 50.9, CH 12 1.57, m 29.4, CH.sub.2 1.43, m 13 1.60, m,1.67, m 20.7, CH.sub.2 13 1.43, m 24.7, CH.sub.2 14 3.28, m 36.0, CH.sub.2 14 3.07, m 40.4, CH.sub.2 3.15, m NH-12 7.53, br s 15 153.8, C 15 156.7, C 16 169.5, C 16 172.0, C NH-14 8.12, br s NH-14 7.57 NH-11 6.70, d (8.4) 17 4.28, m 52.6, CH 17 4.25, m 52.0, CH 18 1.86, m, 1.77, m 31.8, CH 18 1.82, m, 1.74, m 32.0, CH.sub.2 19 2.40, m 29.4, CH.sub.3 19 2.36, m 30.1, CH.sub.3 20 2.01, s 14.6 CH.sub.3 20 1.99, s 14.6, CH.sub.3 21 171.0, C 21 170.5, C NH-17 8.31, d (7.2) NH-17 7.98, d (7.2) 22 3.90, m 52.6, CH 22 3.87, m 52.3, CH 23 2.80, dd (13.8, 6) 36.3, CH.sub.2 23 2.80, dd (13.2, 5.4) 36.4, CH.sub.2 2.64, dd (13.8, 7.2) 2.63, dd (13.2, 8.4) 24 138.8, C 24 138.9, C 25 7.19, ov 129.1, CH 25 7.19, ov 129.1, CH 26 7.25, ov 128.0, CH 26 7.25, ov 128.0, CH 27 7.19, ov 125.9, CH 27 7.19, ov 125.9, CH 28 7.25, ov 128.0, CH 28 7.25, ov 128.0, CH 29 7.19, ov 129.1, CH 29 7.19, ov 129.1, CH 30 3.31, d (5.4) 62.1, CH.sub.2 30 3.29, ov 62.2, CH.sub.2 NH-22 7.96, d (8.4) NH-22 7.74, d (8.4)

Example 8. Determination of Antiviral Activity of the Omicsynins

Determination of the Inhibitory Activity of the Omicsynins Against Influenza Virus H3N2

[0180] The inhibitory effect of some omixins on influenza virus (H3N2) strains was determined by CPE method, and the activity of ribavirin (RBV) was also determined.(shown in Table 9)

TABLE-US-00013 the inhibitory activity of the Omicsynins against influenza virus H3N2 A/Wuhan/359/1995 (H3N2) Sample information TC.sub.50 (.Math.M) IC.sub.50 (.Math.M) SI Omicsynin A1 > 318.83 318.83 ± 0 > 1.00 Omicsynin A2 (2) > 794.53 207.77 ± 56.00 > 3.82 Omicsynin A3 (3) > 335.97 87.85 ± 23.68 > 3.82 Omicsynin A4 (4) > 83.71 > 83.71 - Omicsynin B1 (7) > 315.31 0.89 ± 0.20 - > 352.94 Omicsynin B2 (8) > 314.32 1.00 ± 0.22 > 312.78 Omicsynin B3 (9) > 332.06 3.34 ± 0.13 > 99.34 Omicsynin B4 (10) > 330.96 2.43 ± 0.71 > 136.05 antipain > 330.96 3.16 ± 0.94 > 104.90 chymostatin > 329.33 329.33 ± 0 > 1.00 RBV > 819.00 13.16 ± 3.11 > 62.24

[0181] Sample description: [0182] RBV, ribavirin injection was purchased from Tianjin Jinyao Group Hubei Tianyao Pharmaceutical Co., Ltd., the batch number is 31712252, and the specification is 100 mg/ml, [0183] Antipain (#37682-72-7, 5 mg) was purchased from Shanghai Yifei Biotechnology Co., Ltd., which is equivalent to the monomeric compound Omicsynin B4 obtained from the fermentation sample of Streptomyces CPCC 200451 described in the present disclosure, [0184] Chymostatin (#9076-44-2, 5 mg) was purchased from Sigma-Aldrich Company, the reagent contains three compounds Chymostatin A, B, C, which are equivalent to the compounds Omicsynin C3 and C5 described in the present disclosure,

Activity Assays Were Repeated Three Times and Results Were Expressed as Mean ± SD.

Determination of the Inhibitory Activity of the Omicsynins Against Coronavirus HCoV-229E

[0185] 1. The steps of the anti-HCoV-229E virus activity assay of cytopathic effect (CPE) inhibition assay: [0186] (1) the passaged hepatocyte Huh7.5 cells seeded in 96-well plates at 37° C. overnight (1×10.sup.4 cells/well) ; [0187] (2) Infect cells with the virus at 100 times 50% tissue culture infective dose (TCID50) for 2 h (for HCoV- 229E, the test compound was added simultaneously or administration 2 h after infection), The test compounds are diluted three times for 8 doses, and the positive control drug Ribavirin Injection was diluted to the required concentration when used, [0188] (3) Two parallel wells were set for each dose, and the results were observed when the lesions in the control group reached the CPE evaluation standard 4+. The 50% inhibitory concentration (IC50) was determined by the Reed and Muench method, The 50% toxicity concentration (TC50) of the test samples and positive compounds was also evaluated by the CPE assay. The selectivity index (SI) was calculated as the ratio of TC50/IC50 (shown in Table 10).

[00001]${\text{IC}}_{50}=\underset{¯}{\text{AntiLog}}\left(\text{A}+\frac{\text{B}-50}{50-\text{C}}\times \text{D}\right)$

[0189] Where: A=drug concentration with cumulative inhibition rate<50%, [0190] B=inhibition rate with cumulative inhibition rate>50%, [0191] C=inhibition rate with cumulative inhibition rate<50%, [0192] D=log dilution factor [0193] CPE evaluation criteria: the proportion of cell death was marked as 4+ (75% to 100% of cell death), 3+ (50% to 75% of cell death), 2+ (25% to 50% of cell death), 1+ (cell death ratio 0-25%), 0+ (all cells survive).

[0194] The experiments were repeated more than 2 times, and representative results are given.

TABLE-US-00014 the inhibitory activity of the Omicsynins against coronavirus HCoV-229E HCoV-229E Sample information TC.sub.50 (.Math.M) IC.sub.50 (.Math.M) SI Omicsynin A1 (1) > 159.41 45.04 ± 7.03 > 3.54 Omicsynin A2 (2) > 397.27 171.85 ± 2.10 > 0.92 Omicsynin A3 (3) > 167.98 57.41 ± 15.62 > 2.93 Omicsynin A4 (4) > 41.86 > 41.86 - Omicsynin B1 (7) > 157.65 1.35 ± 0.28 > 117.19 Omicsynin B2 (8) > 157.16 1.53 ± 0.32 > 102.90 Omicsynin B3 (9) > 166.03 1.19 ± 0.51 > 139.53 Omicsynin B4 (10) > 165.48 0.89 ± 0.22 > 186.34 antipain > 165.48 1.57 ± 0.46 > 105.63 chymostatin > 164.66 23.74 ± 5.66 > 6.93 RBV > 409.50 25.14 ± 6.10 > 16.29 Sample description: same as above.

3. Determination of the Inhibitory Activity of the Omicsynins Against Coronavirus HCoV-OC43

qRT-PCR Analysis to Detect the mRNA Expression Level of HCoV-OC43 N Protein in C3A Cells:

[0195] The passaged human hepatoblastoma cell line C3A were seeded in 12-well plates (3.5×105 cells/well), incubated and treated with the indicated concentrations of compounds for 24 hours. Total RNA from infected cells was extracted using the RNeasy Mini kit (QIAGEN). The mRNA expression level of HCoV-OC43 N protein was measured by the ABI 7500 Rapid RT-PCR System (Applied Biosystems) using the TransScriptTM Taqman One-Step qRT-PCR SuperMix Kit (TransGen Biotech), and was corrected for the GAPDH expression level. Using the software GraphPad Prism 8 to calculate the IC50 of the compounds against coronavirus HCoV-OC43.

Determination of the Activity of Omicsynin B4 Against Coronavirus HCoV-OC43

[0196] The results showed that the IC50 of Omicsynin B4 for inhibitory activity of coronavirus HCoV-OC43 was 28.67 .Math.M, and the IC50 of ribavirin (RBV) was determined at the same time, as shown in FIG. 35.

[0197] The above results showed that omicxin compounds also have a good inhibitory effect on coronavirus.

[0198] Finally, it should be noted that the above embodiments are only used to understand the essence of the present disclosure, and are not used to limit the protection scope of the present disclosure.